Efficacy and safety of once‐weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index. Issue 4 (2nd January 2021)

• Record Type: Journal Article
• Authors: Shi, Yongquan; Liu, Siying; Zhu, Jiankun; Hong, Tianpei
• Is Part Of: Journal of diabetes. Volume 13:Issue 4(2021)
• Page Start: 353
• Page End: 357
• Publication Date: 2021-01-02
• Subjects: body mass index -- dulaglutide -- type 2 diabetes; 体重指数 -- 杜拉鲁肽 -- 2型糖尿病; Diabetes -- Periodicals; 618.3646005
• DOI: 10.1111/1753-0407.13147
• Languages: English
• ISSNs: 1753-0393

Abstract

Abstract : Highlights In Chinese patients with type 2 diabetes (T2D) and body mass index (BMI) <25 kg/m 2, dulaglutide demonstrated great improvements in glycemic control with mild body weight reduction and low hypoglycemia risk. The results indicate that dulaglutide is effective and safe in patients with T2D and lower BMI; therefore, BMI should not be a consideration when dulaglutide is prescribed to Chinese patients with T2D.